Manore, S.; Zhuang, C.; Najjar, M.K.; Wong, G.L.; Bindal, S.; Watabe, K.; Lin, J.; Lo, H.-W.
Co-Inhibition of tGLI1 and GP130 Using FDA-Approved Ketoconazole and Bazedoxifene Is Synergistic Against the Growth and Metastasis of HER2-Enriched and Triple-Negative Breast Cancers. Cells 2024, 13, 2087.
https://doi.org/10.3390/cells13242087
AMA Style
Manore S, Zhuang C, Najjar MK, Wong GL, Bindal S, Watabe K, Lin J, Lo H-W.
Co-Inhibition of tGLI1 and GP130 Using FDA-Approved Ketoconazole and Bazedoxifene Is Synergistic Against the Growth and Metastasis of HER2-Enriched and Triple-Negative Breast Cancers. Cells. 2024; 13(24):2087.
https://doi.org/10.3390/cells13242087
Chicago/Turabian Style
Manore, Sara, Chuling Zhuang, Mariana K. Najjar, Grace L. Wong, Shivani Bindal, Kounosuke Watabe, Jiayuh Lin, and Hui-Wen Lo.
2024. "Co-Inhibition of tGLI1 and GP130 Using FDA-Approved Ketoconazole and Bazedoxifene Is Synergistic Against the Growth and Metastasis of HER2-Enriched and Triple-Negative Breast Cancers" Cells 13, no. 24: 2087.
https://doi.org/10.3390/cells13242087
APA Style
Manore, S., Zhuang, C., Najjar, M. K., Wong, G. L., Bindal, S., Watabe, K., Lin, J., & Lo, H.-W.
(2024). Co-Inhibition of tGLI1 and GP130 Using FDA-Approved Ketoconazole and Bazedoxifene Is Synergistic Against the Growth and Metastasis of HER2-Enriched and Triple-Negative Breast Cancers. Cells, 13(24), 2087.
https://doi.org/10.3390/cells13242087
